A new study found no significant benefit in adding low-dose oral glucocorticoids to immunosuppressive therapy for improving skin fibrosis in patients with early diffuse cutaneous systemic ...

Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes.

Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One patient in each treatment group had scleroderma renal crisis. Low doses of ...

Findings from the implanted scaffold led researchers to block specific inflammatory molecules, easing disease severity in a ...

A sponge-like implant in mice has helped guide a treatment that slowed or stopped a degenerative condition similar to ...

Puffy under-eye bags are often related to lifestyle choices, such as smoking or not sleeping enough. Find ways to minimize ...

[2] Patients with diffuse cutaneous scleroderma with skin thickening on the proximal extremities or the trunk are in highest danger of developing SRC, at 20% to 25%, and so should be followed ...

Current asthma treatments don't work in all patients, and they don't provide long-term relief from potentially deadly asthma ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...